Why Chemed Stock Jumped 9% Today

Chemed Corp (NYSE: CHE) rose 9% to $555.17 in regular trading after its third-quarter results beat expectations and it raised its full-year forecast. Strength in its hospice business more than offset weaker plumbing results, giving investors a higher earnings outlook.

What Chemed Corp Does

Vitas provides hospice care for people nearing the end of life, while Roto-Rooter handles plumbing and drain work. These distinct businesses give Chemed different sources of earnings, but either can shape the company’s results.

Chemed Third-Quarter Earnings Beat

Chemed’s quarterly profit exceeded analyst expectations. Earning more than analysts had forecast gives investors a stronger starting point for judging the rest of the year.

Chemed Full-Year Outlook Improves

Chemed’s full-year guidance, its forecast for annual results, now points to stronger earnings. Bank of America, or BofA, said through its analysts assessing Chemed’s forecast that the increase reflects expected continued Vitas strength beyond the quarter already reported.

Chemed Roto-Rooter Territory Buyback

Chemed has also reacquired Roto-Rooter franchise territories, meaning it bought operating rights back from franchise operators. That earlier transaction provides context for the plumbing business, rather than a new deal announcement driving today’s rise.

Quick Financial Overview

Chemed is a profitable mid-cap, a company smaller than the largest public firms, with a market value of $7.26B. It had $40.2M in cash and cash equivalents, meaning cash the company can spend, as of June 30, 2026.

Chemed Adjusted Earnings of $6.75

The company reported adjusted diluted earnings per share of $6.75 for the third quarter. This measure excludes specified items and spreads profit across shares, including shares that could be issued as employee compensation.

Chemed Vitas Patient Revenue

Vitas reported net patient revenue of $457.4 million for the quarter. That is money earned from patient care, showing the scale of the business supporting Chemed’s improved forecast.

Chemed Nears Its 52-week High

Chemed is up 31% over six months, so today’s jump extends a longer climb. Shares pushed toward their yearly high this morning. For Chemed, the last daily move this large was many sessions ago.

Conclusion

Chemed’s next reporting milestone is its next quarterly report, with no date specified. BofA expects the territory buyback to add only modest near-term profit, leaving the existing businesses to carry most of the earnings load. Stronger plumbing results would broaden that support, while further weakness would leave Chemed more reliant on patient care.

Start Your Trial Now!